A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
The Oxford researcher’s work on lipid and peptide antigens revealed key mechanisms in inflammation, immunotherapy, and vaccination, which are being pursued in clinical trial treatments.
Jane Buckner, MD and Carla Greenbaum, MD | Mar 1, 2023 | 4 min read
A therapy for type 1 diabetes is the first to treat patients before symptoms appear, paving the way toward preventing this and other autoimmune diseases.